JP6636915B2 - ユビキチニル化タンパク質 - Google Patents

ユビキチニル化タンパク質 Download PDF

Info

Publication number
JP6636915B2
JP6636915B2 JP2016521645A JP2016521645A JP6636915B2 JP 6636915 B2 JP6636915 B2 JP 6636915B2 JP 2016521645 A JP2016521645 A JP 2016521645A JP 2016521645 A JP2016521645 A JP 2016521645A JP 6636915 B2 JP6636915 B2 JP 6636915B2
Authority
JP
Japan
Prior art keywords
cells
tumor
protein
composition
ubiquitinylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016521645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534042A (ja
JP2016534042A5 (https=
Inventor
クリストファー トウィッティ
クリストファー トウィッティ
エリック ルシェーン
エリック ルシェーン
バーナード フォックス
バーナード フォックス
ホン−ミン フー
ホン−ミン フー
グワンジェ ユイ
グワンジェ ユイ
Original Assignee
ユビバック エルエルシー
ユビバック エルエルシー
プロビデンス ヘルス アンド サービシーズ−オレゴン
プロビデンス ヘルス アンド サービシーズ−オレゴン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユビバック エルエルシー, ユビバック エルエルシー, プロビデンス ヘルス アンド サービシーズ−オレゴン, プロビデンス ヘルス アンド サービシーズ−オレゴン filed Critical ユビバック エルエルシー
Publication of JP2016534042A publication Critical patent/JP2016534042A/ja
Publication of JP2016534042A5 publication Critical patent/JP2016534042A5/ja
Application granted granted Critical
Publication of JP6636915B2 publication Critical patent/JP6636915B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2016521645A 2013-10-11 2014-10-10 ユビキチニル化タンパク質 Active JP6636915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361890054P 2013-10-11 2013-10-11
US61/890,054 2013-10-11
PCT/US2014/060180 WO2015054668A1 (en) 2013-10-11 2014-10-10 Ubiquitinylated proteins

Publications (3)

Publication Number Publication Date
JP2016534042A JP2016534042A (ja) 2016-11-04
JP2016534042A5 JP2016534042A5 (https=) 2017-11-24
JP6636915B2 true JP6636915B2 (ja) 2020-01-29

Family

ID=52809877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016521645A Active JP6636915B2 (ja) 2013-10-11 2014-10-10 ユビキチニル化タンパク質

Country Status (7)

Country Link
US (1) US10226518B2 (https=)
EP (1) EP3055322B1 (https=)
JP (1) JP6636915B2 (https=)
KR (1) KR20160127711A (https=)
CN (1) CN105934442B (https=)
CA (1) CA2926332A1 (https=)
WO (1) WO2015054668A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104877017A (zh) * 2015-05-06 2015-09-02 东南大学 一种抗肿瘤泛素化蛋白及其提取方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241140A1 (en) * 2000-11-01 2004-12-02 Pavlakis George N. Expression vectors able to elicit improved immune response and methods of using same
WO2007016340A2 (en) * 2005-07-29 2007-02-08 Providence Health System Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
WO2007058235A1 (ja) * 2005-11-17 2007-05-24 Medinet Co., Ltd. 融合蛋白質およびその薬学的用途
JP2012039877A (ja) * 2009-04-10 2012-03-01 Fukuoka Univ ユビキチン融合遺伝子およびそれを用いたｄｎａワクチン
EP2608811B1 (en) * 2010-08-27 2015-01-28 Providence Health & Services - Oregon Alumina nanoparticle bioconjugates and methods of stimulating an immune response using said bioconjugates

Also Published As

Publication number Publication date
JP2016534042A (ja) 2016-11-04
EP3055322A4 (en) 2017-06-14
WO2015054668A1 (en) 2015-04-16
US20150104477A1 (en) 2015-04-16
US10226518B2 (en) 2019-03-12
CN105934442A (zh) 2016-09-07
CN105934442B (zh) 2020-03-06
CA2926332A1 (en) 2015-04-16
EP3055322A1 (en) 2016-08-17
EP3055322B1 (en) 2019-09-25
KR20160127711A (ko) 2016-11-04

Similar Documents

Publication Publication Date Title
Zuo et al. Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses
Lee et al. Dendritic cell vaccines: a shift from conventional approach to new generations
US20220064584A1 (en) Delivery of biomolecules to immune cells
Harimoto et al. Inactivation of tumor‐specific CD8+ CTLs by tumor‐infiltrating tolerogenic dendritic cells
Hiltbrunner et al. Exosomal cancer immunotherapy is independent of MHC molecules on exosomes
Jackaman et al. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo
Wada et al. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen
WO2020072700A1 (en) Hla single allele lines
Wang et al. Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway
Yuan et al. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma
US20230145817A1 (en) Neoepitope vaccine and immune stimulant combinations and methods
Draghiciu et al. Therapeutic immunization and local low‐dose tumor irradiation, a reinforcing combination
Montico et al. Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy
Shimizu et al. Vaccination with Antigen-Transfected, NKT Cell Ligand–Loaded, Human Cells Elicits Robust In Situ Immune Responses by Dendritic Cells
WO2013016675A1 (en) Dendritic cell (dc)-vaccine therapy for pancreatic cancer
Zhang et al. Complete remission of tumors in mice with neoantigen-painted exosomes and anti-PD-1 therapy
CN108743937A (zh) 疫苗组合物和方法
KR20200067862A (ko) 종양-관련된 항원 에피토프의 미생물 서열 변이체
JP2019524773A (ja) 樹状細胞のトランスフェクション及びその方法
Luo et al. Engineered mitochondria exert potent antitumor immunity as a cancer vaccine platform
US11564980B2 (en) Tumor treatment method with an individualized peptide vaccine
Ye et al. Engineering cancer cell membranes with endogenously upregulated HSP70 as a reinforced antigenic repertoire for the construction of material-free prophylactic cancer vaccines
JP6636915B2 (ja) ユビキチニル化タンパク質
Kim et al. CD4+ T cells mediate MHC-deficient tumor rejection and endothelial cell reprogramming
Varypataki et al. Combined photosensitization and vaccination enable CD8 T-cell immunity and tumor suppression independent of CD4 T-cell help

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191219

R150 Certificate of patent or registration of utility model

Ref document number: 6636915

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250